Editas Medicine (EDIT) Free Cash Flow (2015 - 2025)

Editas Medicine (EDIT) has reported Free Cash Flow for 11 consecutive years, with -$30.8 million the latest figure, recorded in Q3 2025.

• In Q3 2025, Free Cash Flow rose 44.44% year-over-year to -$30.8 million; the TTM figure through Dec 2025 stood at -$127.8 million (up 41.66% YoY), while the FY2024 annual figure was -$219.1 million, down 60.05% from the prior year.
• Free Cash Flow grew to -$30.8 million in Q3 2025 per EDIT's latest filing, from -$50.2 million in the prior quarter.
• Across five years, Free Cash Flow topped out at -$23.5 million in Q4 2023 and bottomed at -$60.6 million in Q2 2024.
• Historically, Free Cash Flow has averaged -$44.1 million across 5 years, with a median of -$43.1 million in 2021.
• Annual changes were most pronounced in 2023 — Free Cash Flow jumped 45.11% — and 2024, when it tumbled 117.87%.
• Editas Medicine's Free Cash Flow stood at -$37.4 million in 2021, then retreated by 14.62% to -$42.9 million in 2022, then surged by 45.11% to -$23.5 million in 2023, then sank by 117.87% to -$51.3 million in 2024, then soared by 39.88% to -$30.8 million in 2025.
• Business Quant data shows EDIT's Free Cash Flow at -$30.8 million in Q3 2025, -$50.2 million in Q2 2025, and -$46.8 million in Q1 2025.